ArticleClinical rheumatology2009
Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab.
Article in Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.Clinical rheumatology · 2013Pooled it
- The Risk Factors of Refractory Adult-Onset Still's Disease.International journal of hepatology · 2025Article
- Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.Frontiers in medicine · 2022Review
- Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity.Internal medicine (Tokyo, Japan) · 2021Article
- Adult-onset Still's disease evolving with multiple organ failure and death: A case report and review of the literature.World journal of clinical cases · 2021Article
- Mechanisms, biomarkers and targets for adult-onset Still's disease.Nature reviews. Rheumatology · 2018Review
- Tocilizumab (Actemra).Human vaccines & immunotherapeutics · 2017Review
- Review
- Quotidian High Spiking Fevers in Adult Still's Disease.The American journal of case reports · 2017Article
- Three cases of previous smokers with rheumatoid arthritis who did not respond to tumor necrosis factor inhibitors were treated successfully with an anti-interleukin-6 receptor antibody.Case reports in rheumatology · 2015Article
- Treatment of adult-onset Still's disease: a review.Therapeutics and clinical risk management · 2015Review
- Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease.Case reports in rheumatology · 2015Article
- Life-threatening complications of adult-onset Still's disease.Clinical rheumatology · 2014Review
- Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.Clinical rheumatology · 2014Article
- Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease.Clinical rheumatology · 2013Article
- Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.Clinical rheumatology · 2012Review
- Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.International journal of inflammation · 2012Article
- Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.International journal of biological sciences · 2012Review
- Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.International journal of rheumatology · 2012Article
- Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature.Rheumatology international · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a 29-year-old Japanese woman with disseminated intravascular coagulation (DIC) and adult onset Still's disease (AOSD). Her disease was refractory to high-dose glucocorticoids, two courses of steroid pulse therapy, and addition of cyclosporine (3.5 mg/kg/day). The serum interleukin-6 level was markedly elevated. Therefore, we administered an anti-interleukin-6 receptor antibody (tocilizumab, 8 mg/kg fortnightly), which dramatically improved her symptoms and the levels of acute-phase proteins. In addition, rapid tapering of the glucocorticoid dose was possible. Four months later, she was maintained on tocilizumab infusion once a month with low-dose steroid therapy. Cyclosporine is one of the first-line immunosuppressants for AOSD, especially when associated with DIC, hepatic failure, or hemophagocytic syndrome. In patients with cyclosporine-resistant AOSD, tocilizumab may be another useful option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.